INTRODUCTION
The therapeutic vaccines sector is yet to see the launch of a significant product in the seven major markets. Despite the unproven commercial
potential, the sector is commanding considerable interest across the biotechnology industry - Datamonitor has identified 65 companies developing
therapeutic vaccines, with 167 products in development.
SCOPE OF THE REPORT
- Benchmarking of the current and future vaccine market, by technology and therapeutic focus, in terms of number of projects and dollar value
- Identification of the steps that emerging players are taking to increase innovation in their businesses, integrate supply chain and improve
strategic position
- Analysis of market trends and future opportunities for both biotech and pharmaceutical players, with supporting case studies
- Full profiles of 6 leading therapeutic vaccine players, encompassing company strategy, alliance networking, portfolio and pipeline analysis
REPORT HIGHLIGHTS
The therapeutic vaccine market will not receive significant attention from the wider pharmaceutical industry until a product is launched and
achieves significant market uptake. The most likely drug to achieve this is Dendreon's Provenge, although Dendreon must recruit a marketing partner
before this can be achieved.
Companies that are totally focused on therapeutic vaccines will need to develop a strong network of partners to
survive. Their ability to form partnerships is being inhibited by the unproven technology behind therapeutic vaccines, and the number of setbacks that
leading products have encountered
Oncology dominates therapeutic vaccines both in terms of commercial potential and pipeline development, with
colorectal, melanoma and prostate cancer having most therapeutic vaccines in development. The early stage pipeline is split across more therapy areas,
with an increased focus on infectious disease, CNS and HIV.
KEY REASONS TO BUY THIS REPORT
- Select the optimum strategy for future success in the vaccine sector
- Recognize new opportunities for therapeutic vaccines presented by advances in science and changes in the commercial environment
- Identify pipeline products for in-licensing, and areas of unmet need
View Cart
